AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares
(WorldNews Switzerland)

Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that it is commencing offerings of up to 10 million new common shares of the Company with a nominal value of CHF 0.02 each. The Company intends to issue all new common shares against cash contributions as approved by the Company`s shareholders. The Company plans to use the proceeds from the offerings primarily to fund research and development expenses for the Company`s clinical and pre-clinical research and development activities, for working capital and the remainder for general corporate purposes. The offerings...